Utama › Kanser Gastrointestinal › California

Kajian klinikal Kanser Gastrointestinal di California

28 kajian untuk Kanser Gastrointestinal sedang mencari peserta di lokasi di California.

Bandar di California

Teks kajian rasmi (Bahasa Inggeris)

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
Mercy Cancer Center - Carmichael, Carmichael
Mercy San Juan Medical Center, Carmichael
dan 8 lagi

Mengambil pesertaSukarelawan sihat dialu-alukan

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07283939

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

City of Hope Duarte, Duarte
University of California at Los Angeles, Santa Monica

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07529808

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

City of Hope - Duarte Cancer Center, Duarte

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06760819

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

UCSF at Berkeley Outpatient Center, Berkeley
Alta Bates Summit Medical Center-Herrick Campus Comprehensive Cancer Center, Berkeley
UCSD Medical Center - Encinitas, Encinitas
dan 21 lagi

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07222800

DESTINY-PANTUMOUR04

Research Site, San Diego

Mengambil pesertaKajian pemerhatian

Umur 18 hingga 130 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07124000

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GSK Investigational Site, Duarte
GSK Investigational Site, La Jolla
GSK Investigational Site, Los Angeles
dan 3 lagi

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07218926

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

UC IRVINE Health, Orange
UC Davis Comprehensive Cancer Center, Sacramento
Stanford Cancer Institute, Stanford

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

UC San Diego Moores Cancer Center, La Jolla
Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles
UCLA Hematology/Oncology- Santa Monica, Los Angeles

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06445062

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Stanford Cancer Center, Palo Alto

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05274048

Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

University of California, San Francisco, San Francisco

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06633224

Personalized Health Self-Management Training for Colorectal Cancer Survivors

University of Southern California, Los Angeles

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05984589

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

University of Southern California, Los Angeles
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
Cedars-Sanai Medical Center, Los Angeles
dan 1 lagi

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06582017

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

City of Hope, Duarte
Hoag Memorial Hospital Presbyterian, Newport Beach

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT07544589

Understanding New Cachexia Subtypes Through Observational Epidemiological Research

Kaiser Permanente Northern California, Pleasanton

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07776353

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

University of California, San Francisco, San Francisco
John Muir Medical Center-Walnut Creek, Walnut Creek

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT04221893

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

GSK Investigational Site, Los Alamitos
GSK Investigational Site, Los Angeles
GSK Investigational Site, Santa Monica
dan 1 lagi

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06885034

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

City of Hope Nat Medical Ctr, Duarte

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan

Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07224750

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

USC Norris Comprehensive Cancer Center, Los Angeles

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07337525

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

University of California, Davis Comprehensive Cancer Center, Sacramento

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT06040541

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

St Joseph Heritage Healthcare, Santa Rosa

Mengambil pesertaFasa 1/2

Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

UC Irvine/Chao Family Comprehensive Cancer Center, Orange
UCLA, Santa Monica

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Cedars-Sinai Medical Center, Los Angeles

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT07020221

Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions

Interventional Endoscopy Services, San Francisco

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Mac 2026 · NCT01750619

PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

Mengambil pesertaFasa awal 1

Umur 18 ke atas · Semua jantina · Dikemas kini 27 Feb 2026 · NCT06511037

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Cedars-Sinai Medical Center, Los Angeles

Mengambil peserta

Umur 18 hingga 99 · Semua jantina · Dikemas kini 20 Feb 2026 · NCT04907643

Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

Cedars-Sinai Medical Center, Los Angeles

Mengambil pesertaFasa 4

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2025 · NCT07124351

Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System

City Of Hope, Duarte
Stanford Cancer Center, Palo Alto

Mengambil pesertaKajian pemerhatian

Semua umur · Semua jantina · Dikemas kini 15 Ogo 2025 · NCT05406167

Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

City of Hope, Duarte

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2023 · NCT06002425

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.